Human Recombinant Insulin Market Share

Statistics for the 2023 & 2024 Human Recombinant Insulin market share, created by Mordor Intelligence™ Industry Reports. Human Recombinant Insulin share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Human Recombinant Insulin Industry

The human recombinant insulin market studied is consolidated, as there are few companies that are dominating the market currently. Some of the key players that have a considerable share of this market include Eli Lilly and Company, Novo Nordisk, and Sanofi S.A., among others.

Human Recombinant Insulin Market Leaders

  1. Novo Nordisk A/S

  2. Eli Lilly and Company

  3. Sanofi S.A.

  4. Biocon

  5. Zhuhai United Laboratories Co., Ltd.

*Disclaimer: Major Players sorted in no particular order

Human Recombinant Insulin Market Concentration

Human Recombinant Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)